HROW - Harrow Health Inc logo

Harrow Health Inc

HROW

Harrow Health develops and commercializes ophthalmic pharmaceutical products, including compounded medications through ImprimisRx. Its portfolio features various eye drops and gels for conditions like age-related macular degeneration and bacterial conjunctivitis.

⚕️ Healthcare NASDAQ Listed 2007 $ USD
$1,000 invested 10 years ago →$9,512today

Score Overview

1 Year
Score
Net Growth-5x
Net TrendShrank
Net Income Consistency—
Rev Growth1.21%
Rev TrendGrew
Revenue Consistency—
5 Years
Score5.7
Net Growth-106.73%
Net Trend60%
Net Income Consistency—
Rev Growth280.26%
Rev TrendEvery year
Revenue Consistency—
10 Years
Score
Net Growth-95.03%
Net Trend50%
Net Income Consistency
Rev Growth13x
Rev Trend90%
Revenue Consistency
All Time
Score—
Net Growth-6x
Net Trend42%
Net Income Consistency
Rev Growth—
Rev Trend92%
Revenue Consistency

Explore the 2021 public Archive ranking →

Where Harrow Health Inc has ranked, year by year

Measure
Fundamentals Window

Showing 10 years ranking history by Net Income Growth.

Has not reached the top 50 on Net Income Growth in any year we have ranked.

  • HROW

2018: 91.3% · 2021: 65.8% · free through 2021 · longest runs

Net Income x Stock Price

Historical Returns

Historical Returns
PeriodPriceReturn
Last Price2026-10-23
$ 28.44—
1 Year2025-10-23
$ 39.04-27.15%
5 Years2021-10-22
$ 9.74191.99%
10 Years2016-10-21
$ 2.999x

Prices are split & dividend adjusted. All values are reported in USD.

Fundamental Data

Reported in USD

Year
TTM$ 275M-$ 37M$ 83M
2025$ 272M-$ 5M$ 72M
2024$ 199M-$ 17M$ 47M
2023$ 130M-$ 24M$ 82M
2022$ 88M-$ 14M$ 96M
2021$ 72M-$ 18M$ 50M
2020$ 48M-$ 3M$ 32M
2019$ 51M$ 168K$ 29M
2018$ 41M$ 14M$ 28M
2017$ 26M-$ 11M$ 4M
2016$ 19M-$ 19M$ 8M
2015$ 9M-$ 15M$ 2M
2014$ 1M-$ 10M$ 8M
2013-$ 7M$ 15M
2012$ 100K-$ 5M$ 10M
2011-$ 954K$ 146.16K
2010-$ 2M
2009-$ 4M$ 1M
2008-$ 3M$ 5M
IPO2007-$ 4M$ 3M
HROW - Harrow Health Inc logo

Harrow Health Inc fundamental performance

Between 2020 and 2025, revenue grew from $ 48M to $ 272M and net income went from -$ 3M to -$ 5M. Revenue increased in every one of those 5 years; net income in 3.

Between 2015 and 2025, revenue grew from $ 9M to $ 272M and net income went from -$ 15M to -$ 5M. Revenue increased in 9 of those 10 years; net income in 5.

Harrow Health Inc currently holds a 5-year HDB Score of 5.7 out of 10. How the HDB Score is calculated.

Membership

Continue HROW’s history

The public Archive runs through 2021. Membership adds recent and current rankings.

  • Recent and current rankings across 5,112 companies
  • Compare companies with the latest data
  • Track your research shortlist in a portfolio

$99 / year

$149/year · Founding price

Continue with Membership

30-day money-back guarantee.

Explore other companies